Inflammation-sleep interface in brain disease: TNF, insulin, orexin

Journal of Neuroinflammation

Volumn 11, Issue , 2014, Pages

  Clark, Ian A ^a   Vissel, Bryce ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Alzheimer's disease; coma; encephalopathy; IL 1; orexin; Parkinson's disease; sleep; stroke; TNF; traumatic brain injury

Indexed keywords

BRANCHED CHAIN AMINO ACID; CYTOKINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; INSULIN; ISOLEUCINE; LEUCINE; OREXIN; TUMOR NECROSIS FACTOR; VALINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; APPETITE; BRAIN DISEASE; BRAIN RADIATION; BURN; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY; COGNITION; COGNITIVE DEFECT; COMA; DAYTIME SOMNOLENCE; DISEASE SEVERITY; DISEASES; HUMAN; IATROGENIC DISEASE; ILLNESS BEHAVIOR; INFLAMMATION; INFLAMMATORY DISEASE; INFLUENZA; INJURY; INSULIN RESISTANCE; LOSS OF APPETITE; MALARIA; MOTOR CONTROL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; REVIEW; SEPSIS; SLEEP; SLEEP PATTERN; TRAUMATIC BRAIN INJURY; TRYPANOSOMIASIS; UNCONSCIOUSNESS;

ANIMALS; BRAIN DISEASES; HUMANS; INFLAMMATION; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; SLEEP DISORDERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899156712     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-11-51     Document Type: Review

References (174)

1. Franchi L, Eigenbrod T, Nunez G. Cutting edge: TNF-α mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. J Immunol 2009, 183:792-796. 10.4049/jimmunol.0900173, 2754237, 19542372.
2. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, de Woody K, Feldmann M, Maini RN. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999, 163:1521-1528.
3. Le J, Vilcek J. Tumor necrosis factor and interleukin-1: cytokines with multiple overlapping biological activities. Lab Invest 1987, 56:234-248.
4. Zhang Y, Lin JX, Vilcek J. Synthesis of interleukin 6 (interferon-β2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. J Biol Chem 1988, 263:6177-6182.
5. Hong S, Li R, Xu Q, Secombes CJ, Wang T. Two types of TNF-α exist in teleost fish: phylogeny, expression, and bioactivity analysis of Type-II TNF-α3 in rainbow trout Oncorhynchus mykiss. J Immunol 2013, 191(12):5959-5972. 10.4049/jimmunol.1301584, 24244011.
6. Beck G, Vasta GR, Marchalonis JJ, Habicht GS. Characterization of interleukin-1 activity in tunicates. Comp Biochem Physiol B 1989, 92:93-98.
7. Kaslin J, Nystedt JM, Ostergard M, Peitsaro N, Panula P. The orexin/hypocretin system in zebrafish is connected to the aminergic and cholinergic systems. J Neurosci 2004, 24:2678-2689. 10.1523/JNEUROSCI.4908-03.2004, 15028760.
8. LeRoith D, Lesniak MA, Roth J. Insulin in insects and annelids. Diabetes 1981, 30:70-76. 10.2337/diab.30.1.70, 6785127.
9. Clark IA, Alleva LE, Mills AC, Cowden WB. Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev 2004, 17:509-539. 10.1128/CMR.17.3.509-539.2004, 452556, 15258091.
10. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109:129-135. 10.1016/0016-5085(95)90277-5, 7797011.
11. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001, 357:1842-1847. 10.1016/S0140-6736(00)04954-0, 11410193.
12. Paramarta JE, Baeten D, De Rycke L. Synovial tissue response to treatment with TNF blockers in peripheral spondyloarthritis. Open Rheumatol J 2011, 5:127-132. 10.2174/1874312901105010127, 3263444, 22279512.
13. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344:1105-1110. 10.1016/S0140-6736(94)90628-9, 7934491.
14. Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006, 26:2467-2473. 10.1523/JNEUROSCI.5253-05.2006, 16510725.
15. Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor α antibody. Gut 2001, 49:725-728. 10.1136/gut.49.5.725, 1728519, 11600479.
16. Remberger M, Ringden O, Markling L. TNF α levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD. Bone Marrow Transplant 1995, 15:99-104.
17. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K, Akira S, Yamamoto A, Komuro I, Otsu K. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 2012, 485:251-255. 10.1038/nature10992, 3378041, 22535248.
18. Scharfe-Nugent A, Corr SC, Carpenter SB, Keogh L, Doyle B, Martin C, Fitzgerald KA, Daly S, O'Leary JJ, O'Neill LA. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol 2012, 188:5706-5712. 10.4049/jimmunol.1103454, 22544937.
19. Oliff A, Defeo-Jones D, Boyer M, Martinez D, Kiefer D, Vuocolo G, Wolfe A, Socher SH. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987, 50:555-563. 10.1016/0092-8674(87)90028-6, 3607879.
20. Smedley H, Katrak M, Sikora K, Wheeler T. Neurological effects of recombinant human interferon. BMJ 1983, 286:262-264. 10.1136/bmj.286.6361.262, 1546481, 6402063.
21. McAdam KP, Li J, Knowles J, Foss NT, Dinarello CA, Rosenwasser LJ, Selinger MJ, Kaplan MM, Goodman R, Herbert PN, Bausserman LL, Nadler LM. The biology of SAA: identification of the inducer, in vitro synthesis, and heterogeneity demonstrated with monoclonal antibodies. Ann NY Acad Sci 1982, 389:126-136. 10.1111/j.1749-6632.1982.tb22131.x, 6807176.
22. Krueger JM, Walter J, Dinarello CA, Wolff SM, Chedid L. Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol 1984, 246:R994-R999.
23. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975, 72:3666-3670. 10.1073/pnas.72.9.3666, 433057, 1103152.
24. Clark IA, Virelizier J-L, Carswell EA, Wood PR. Possible importance of macrophage-derived mediators in acute malaria. Infect Immun 1981, 32:1058-1066. 351558, 6166564.
25. Clark IA. Suggested importance of monokines in pathophysiology of endotoxin shock and malaria. Klin Wochenschr 1982, 60:756-758. 10.1007/BF01716573, 6181289.
26. Shoham S, Davenne D, Cady AB, Dinarello CA, Krueger JM. Recombinant tumor necrosis factor and interleukin-1 enhance slow-wave sleep. Am J Physiol 1987, 253:R142-R149.
27. Kapas L, Krueger JM. Tumor necrosis factor-beta induces sleep, fever, and anorexia. Am J Physiol 1992, 263:R703-R707.
28. Krueger JM, Takahashi S, Kapás L, Bredow S, Roky R, Fang J, Floyd R, Renegar KB, Guha-Thakurta N, Novitsky S, Obál F. Cytokines in sleep regulation. Adv Neuroimmunol 1995, 5:171-188. 10.1016/0960-5428(95)00007-O, 7496611.
29. Floyd RA, Krueger JM. Diurnal variation of TNFα in the rat brain. Neuroreport 1997, 8:915-918. 10.1097/00001756-199703030-00020, 9141064.
30. Haack M, Pollmacher T, Mullington JM. Diurnal and sleep-wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers. Brain Behav Immun 2004, 18:361-367. 10.1016/j.bbi.2003.12.009, 15157953.
31. Takahashi S, Tooley DD, Kapas L, Fang JD, Seyer JM, Krueger JM. Inhibition of tumor necrosis factor in the brain suppresses rabbit sleep. Eur J Physiol 1995, 431:155-160.
32. Kapas L, Bohnet SG, Traynor TR, Majde JA, Szentirmai E, Magrath P, Taishi P, Krueger JM. Spontaneous and influenza virus-induced sleep are altered in TNF-α double-receptor deficient mice. J Appl Physiol 2008, 105:1187-1198. 10.1152/japplphysiol.90388.2008, 2576045, 18687977.
33. Zielinski MR, Krueger JM. Sleep and innate immunity. Front Biosci (Schol Ed) 2011, 3:632-642. 10.2741/s176, 3645929, 21196401.
34. Slats D, Claassen JA, Verbeek MM, Overeem S. Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin. Ageing Res Rev 2013, 12:188-200. 10.1016/j.arr.2012.04.003, 22575905.
35. Williams JG, Bernstein S, Prager M. Effect of melatonin on activated macrophage TNF, IL-6, and reactive oxygen intermediates. Shock 1998, 9:406-411. 10.1097/00024382-199806000-00003, 9645491.
36. Sasaki M, Jordan P, Joh T, Itoh M, Jenkins M, Pavlick K, Minagar A, Alexander SJ. Melatonin reduces TNF-α induced expression of MAdCAM-1 via inhibition of NF-κB. BMC Gastroenterol 2002, 2:9. 10.1186/1471-230X-2-9, 111062, 12003644.
37. Espino J, Rodriguez AB, Pariente JA. The inhibition of TNF-α-induced leucocyte apoptosis by melatonin involves membrane receptor MT1/MT2 interaction. J Pineal Res 2013, 54:442-452.
38. Fernandes PA, Cecon E, Markus RP, Ferreira ZS. Effect of TNF-α on the melatonin synthetic pathway in the rat pineal gland: basis for a 'feedback' of the immune response on circadian timing. J Pineal Res 2006, 41:344-350. 10.1111/j.1600-079X.2006.00373.x, 17014691.
39. Li J, Hu Z, de Lecea L. The hypocretins/orexins: integrators of multiple physiological functions. Br J Pharmacol 2014, 171:332-350. 10.1111/bph.12415, 24102345.
40. Alvarez CE, Sutcliffe JG. Hypocretin is an early member of the incretin gene family. Neurosci Lett 2002, 324:169-172. 10.1016/S0304-3940(02)00195-7, 12009515.
41. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013, 17:819-837. 10.1016/j.cmet.2013.04.008, 23684623.
42. Chase MH. A unified survival theory of the functioning of the hypocretinergic system. J Appl Physiol 2013, 115:954-971. 10.1152/japplphysiol.00700.2012, 23640599.
43. Sutcliffe JG, de Lecea L. The hypocretins: excitatory neuromodulatory peptides for multiple homeostatic systems, including sleep and feeding. J Neurosci Res 2000, 62:161-168. 10.1002/1097-4547(20001015)62:2<161::AID-JNR1>3.0.CO;2-1, 11020209.
44. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585. 10.1093/brain/awm090, 17470494.
45. Boutrel B, Cannella N, de Lecea L. The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res 2010, 1314:103-111.
46. Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000, 12:726-730. 10.1046/j.1460-9568.2000.00919.x, 10712652.
47. Iliff JJ, Lee H, Yu M, Feng T, Logan J, Nedergaard M, Benveniste H. Brain-wide pathway for waste clearance captured by contrast-enhanced MRI. J Clin Invest 2013, 123:1299-1309. 10.1172/JCI67677, 3582150, 23434588.
48. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377. 10.1126/science.1241224, 24136970.
49. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007. 10.1126/science.1180962, 2789838, 19779148.
50. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology - a bidirectional relationship. Nat Rev Neurol 2014, 10:115-119.
51. Torterolo P, Ramos OV, Sampogna S, Chase MH. Hypocretinergic neurons are activated in conjunction with goal-oriented survival-related motor behaviors. Physiol Behav 2011, 104:823-830. 10.1016/j.physbeh.2011.07.032, 21839102.
52. Xanthos DN, Sandkuhler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci 2014, 15:43-53.
53. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989, 86:7606-76010. 10.1073/pnas.86.19.7606, 298115, 2508093.
54. Donnelly RJ, Friedhoff AJ, Beer B, Blume AJ, Vitek MP. Interleukin-1 stimulates the beta-amyloid precursor protein promoter. Cell Mol Neurobiol 1990, 10:485-495. 10.1007/BF00712843, 2091832.
55. Ge YW, Lahiri DK. Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. Ann NY Acad Sci 2002, 973:463-467. 10.1111/j.1749-6632.2002.tb04684.x, 12485912.
56. He P, Zhong Z, Lindholm K, Berning L, Lee W, Lemere C, Staufenbiel M, Li R, Shen Y. Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice. J Cell Biol 2007, 178:829-841. 10.1083/jcb.200705042, 2064547, 17724122.
57. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon-γ and tumor necrosis factor-α regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 2007, 170:680-692. 10.2353/ajpath.2007.060378, 1851864, 17255335.
58. Zhao J, O'Connor T, Vassar R. The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis. J Neuroinflammation 2011, 8:150. 10.1186/1742-2094-8-150, 3216000, 22047170.
59. He P, Cheng X, Staufenbiel M, Li R, Shen Y. Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of β-secretase in a mouse model of Alzheimer's disease. PLoS One 2013, 8:e55091. 10.1371/journal.pone.0055091, 3566218, 23405115.
60. Medana IM, Day NP, Hien TT, Mai NT, Bethell D, Phu NH, Farrar J, Esiri MM, White NJ, Turner GD. Axonal injury in cerebral malaria. Am J Pathol 2002, 160:655-666. 10.1016/S0002-9440(10)64885-7, 1850649, 11839586.
61. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 2004, 25:419-429. 10.1016/S0197-4580(03)00127-1, 15013562.
62. Miklossy J, Kis A, Radenovic A, Miller L, Forro L, Martins R, Reiss K, Darbinian N, Darekar P, Mihaly L, Khalili K. Beta-amyloid deposition and Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol Aging 2006, 27:228-236. 10.1016/j.neurobiolaging.2005.01.018, 15894409.
63. McCoy JG, Strecker RE. The cognitive cost of sleep lost. Neurobiol Learn Mem 2011, 96:564-582. 10.1016/j.nlm.2011.07.004, 3614362, 21875679.
64. Kalman J, Juhasz A, Bogats G, Babik B, Rimanoczy A, Janka Z, Penke B, Palotas A. Elevated levels of inflammatory biomarkers in the cerebrospinal fluid after coronary artery bypass surgery are predictors of cognitive decline. Neurochem Int 2006, 48:177-180. 10.1016/j.neuint.2005.10.007, 16337034.
65. Terrando N, Monaco C, Ma D, Foxwell BM, Feldmann M, Maze M. Tumor necrosis factor-α triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci USA 2010, 107:20518-20522. 10.1073/pnas.1014557107, 2996666, 21041647.
66. Wu X, Lu Y, Dong Y, Zhang G, Zhang Y, Xu Z, Culley DJ, Crosby G, Marcantonio ER, Tanzi RE, Xie Z. The inhalation anesthetic isoflurane increases levels of proinflammatory TNF-α, IL-6, and IL-1β. Neurobiol Aging 2012, 33:1364-1378. 10.1016/j.neurobiolaging.2010.11.002, 3117127, 21190757.
67. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:41-42. 10.1038/464041a, 2857339, 20203598.
68. Aurell J, Elmqvist D. Sleep in the surgical intensive care unit: continuous polygraphic recording of sleep in nine patients receiving postoperative care. Br Med J (Clin Res Ed) 1985, 290:1029-1032. 10.1136/bmj.290.6474.1029, 1418327, 3921096.
69. Friese RS, Diaz-Arrastia R, McBride D, Frankel H, Gentilello LM. Quantity and quality of sleep in the surgical intensive care unit: are our patients sleeping?. J Trauma 2007, 63:1210-1214. 10.1097/TA.0b013e31815b83d7, 18212640.
70. Alkadhi K, Zagaar M, Alhaider I, Salim S, Aleisa A. Neurobiological consequences of sleep deprivation. Curr Neuropharmacol 2013, 11:231-249. 10.2174/1570159X11311030001, 3648777, 24179461.
71. Frey DJ, Fleshner M, Wright KP. The effects of 40 hours of total sleep deprivation on inflammatory markers in healthy young adults. Brain Behav Immun 2007, 21:1050-1057. 10.1016/j.bbi.2007.04.003, 17524614.
72. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988, 12:123-137. 10.1016/S0149-7634(88)80004-6, 3050629.
73. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21:153-160. 10.1016/j.bbi.2006.09.006, 1850954, 17088043.
74. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 2001, 933:222-234.
75. Cavadini G, Petrzilka S, Kohler P, Jud C, Tobler I, Birchler T, Fontana A. TNF-α suppresses the expression of clock genes by interfering with E-box-mediated transcription. Proc Natl Acad Sci USA 2007, 104:12843-12848. 10.1073/pnas.0701466104, 1937554, 17646651.
76. Hart PH, Whitty GA, Piccoli DS, Hamilton JA. Synergistic activation of human monocytes by granulocyte-macrophage colony-stimulating factor and IFN-γ. Increased TNF-α but not IL-1 activity. J Immunol 1988, 141:1516-1521.
77. Clark IA, Budd AC, Alleva LM. Sickness behaviour pushed too far - the basis of the syndrome seen in severe protozoal, bacterial and viral diseases and post-trauma. Malar J 2008, 7:208. 10.1186/1475-2875-7-208, 2576339, 18854046.
78. Wu YH, Fischer DF, Kalsbeek A, Garidou-Boof ML, van der Vliet J, van Heijningen C, Liu RY, Zhou JN, Swaab DF. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the 'master clock'. FASEB J 2006, 20:1874-1876. 10.1096/fj.05-4446fje, 16818472.
79. Bonanni E, Maestri M, Tognoni G, Fabbrini M, Nucciarone B, Manca ML, Gori S, Iudice A, Murri L. Daytime sleepiness in mild and moderate Alzheimer's disease and its relationship with cognitive impairment. J Sleep Res 2005, 14:311-317. 10.1111/j.1365-2869.2005.00462.x, 16120107.
80. Lee JH, Bliwise DL, Ansari FP, Goldstein FC, Cellar JS, Lah JJ, Levey AI. Daytime sleepiness and functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2007, 15:620-626. 10.1097/JGP.0b013e3180381521, 17586786.
81. Rye DB. Excessive daytime sleepiness and unintended sleep in Parkinson's disease. Curr Neurol Neurosci Rep 2006, 6:169-176. 10.1007/s11910-996-0041-8, 16522272.
82. Poryazova R, Benninger D, Waldvogel D, Bassetti CL. Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants. Eur Neurol 2010, 63:129-135. 10.1159/000276402, 20090346.
83. Castriotta RJ, Murthy JN. Sleep disorders in patients with traumatic brain injury: a review. CNS Drugs 2011, 25:175-185. 10.2165/11584870-000000000-00000, 21062105.
84. Ponsford JL, Parcell DL, Sinclair KL, Roper M, Rajaratnam SM. Changes in sleep patterns following traumatic brain injury: a controlled study. Neurorehabil Neural Repair 2013, 27:613-621. 10.1177/1545968313481283, 23549523.
85. Bliwise DL, Rye DB, Dihenia B, Gurecki P. Greater daytime sleepiness in subcortical stroke relative to Parkinson's disease and Alzheimer's disease. J Geriatr Psychiatry Neurol 2002, 15:61-67. 10.1177/089198870201500202, 12083594.
86. Sterr A, Herron K, Dijk DJ, Ellis J. Time to wake-up: sleep problems and daytime sleepiness in long-term stroke survivors. Brain Inj 2008, 22:575-579. 10.1080/02699050802189727, 18568710.
87. Liu JC, Hung HL, Shyu YK, Tsai PS. The impact of sleep quality and daytime sleepiness on global quality of life in community-dwelling patients with heart failure. J Cardiovasc Nurs 2011, 26:99-105.
88. Riegel B, Ratcliffe SJ, Sayers SL, Potashnik S, Buck HG, Jurkovitz C, Fontana S, Weaver TE, Weintraub WS, Goldberg LR. Determinants of excessive daytime sleepiness and fatigue in adults with heart failure. Clin Nurs Res 2012, 21:271-293. 10.1177/1054773811419842, 3501004, 21878581.
89. Nakanishi-Minami T, Kishida K, Funahashi T, Shimomura I. Sleep-wake cycle irregularities in type 2 diabetics. Diabetol Metab Syndr 2012, 4:18. 10.1186/1758-5996-4-18, 3406980, 22551206.
90. Ptitsyn AA, Zvonic S, Conrad SA, Scott LK, Mynatt RL, Gimble JM. Circadian clocks are resounding in peripheral tissues. PLoS Comput Biol 2006, 2:e16. 10.1371/journal.pcbi.0020016, 1391918, 16532060.
91. Tahara Y, Otsuka M, Fuse Y, Hirao A, Shibata S. Refeeding after fasting elicits insulin-dependent regulation of Per2 and Rev-erbα with shifts in the liver clock. J Biol Rhythms 2011, 26:230-240. 10.1177/0748730411405958, 21628550.
92. Kuriyama K, Sasahara K, Kudo T, Shibata S. Daily injection of insulin attenuated impairment of liver circadian clock oscillation in the streptozotocin-treated diabetic mouse. FEBS Lett 2004, 572:206-210. 10.1016/j.febslet.2004.07.036, 15304349.
93. Ahren B. The future of incretin-based therapy: novel avenues - novel targets. Diabetes Obes Metab 2011, 1:158-166.
94. Dantzer R, Gheusi G, Johnson RW, Kelley KW. Central administration of insulin-like growth factor-1 inhibits lipopolysaccharide-induced sickness behavior in mice. Neuroreport 1999, 10:289-292. 10.1097/00001756-199902050-00015, 10203323.
95. Bluthe RM, Kelley KW, Dantzer R. Effects of insulin-like growth factor-I on cytokine-induced sickness behavior in mice. Brain Behav Immun 2006, 20:57-63. 2907139, 16364817.
96. Idris I, Abdulla H, Tilbrook S, Dean R, Ali N. Exenatide improves excessive daytime sleepiness and wakefulness in obese patients with type 2 diabetes without obstructive sleep apnoea. J Sleep Res 2013, 22:70-75. 10.1111/j.1365-2869.2012.01030.x, 22716195.
97. Clark IA, Vissel B. Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease. Biochem Pharmacol 2013, 86:862-871. 10.1016/j.bcp.2013.07.030, 23939185.
98. McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 2014, 76A:57-67.
99. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K, Brossi A, Lahiri DK, Mattson MP, Hoffer BJ, Wang Y, Greig NH. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 2009, 106:1285-1290. 10.1073/pnas.0806720106, 2633544, 19164583.
100. Rachmany L, Tweedie D, Li Y, Rubovitch V, Holloway HW, Miller J, Hoffer BJ, Greig NH, Pick CG. Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice. Age (Dordr) 2013, 35:1621-1636. 10.1007/s11357-012-9464-0, 22892942.
101. Tweedie D, Rachmany L, Rubovitch V, Lehrmann E, Zhang Y, Becker KG, Perez E, Miller J, Hoffer BJ, Greig NH, Pick CG. Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice. Exp Neurol 2013, 239:170-182. 3534795, 23059457.
102. Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, Iverfeldt K, Tracy LM, Grankvist N, Sjoholm A, Patrone C. Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats. Clin Sci (Lond) 2012, 122:473-483. 10.1042/CS20110374, 3268352, 22150224.
103. Becskei C, Riediger T, Hernadfalvy N, Arsenijevic D, Lutz TA, Langhans W. Inhibitory effects of lipopolysaccharide on hypothalamic nuclei implicated in the control of food intake. Brain Behav Immun 2008, 22:56-64. 10.1016/j.bbi.2007.06.002, 17624718.
104. Gaykema RP, Goehler LE. Lipopolysaccharide challenge-induced suppression of Fos in hypothalamic orexin neurons: their potential role in sickness behavior. Brain Behav Immun 2009, 23:926-930. 10.1016/j.bbi.2009.03.005, 2792632, 19328847.
105. Grossberg AJ, Zhu X, Leinninger GM, Levasseur PR, Braun TP, Myers MG, Marks DL. Inflammation-induced lethargy is mediated by suppression of orexin neuron activity. J Neurosci 2011, 31:11376-11386. 10.1523/JNEUROSCI.2311-11.2011, 3155688, 21813697.
106. Zhan S, Cai GQ, Zheng A, Wang Y, Jia J, Fang H, Yang Y, Hu M, Ding Q. Tumor necrosis factor-alpha regulates the Hypocretin system via mRNA degradation and ubiquitination. Biochim Biophys Acta 2011, 1812:565-571. 10.1016/j.bbadis.2010.11.003, 3042489, 21094253.
107. Baumann CR, Stocker R, Imhof HG, Trentz O, Hersberger M, Mignot E, Bassetti CL. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 2005, 65:147-149. 10.1212/01.wnl.0000167605.02541.f2, 16009905.
108. Baumann CR, Werth E, Stocker R, Ludwig S, Bassetti CL. Sleep-wake disturbances 6 months after traumatic brain injury: a prospective study. Brain 2007, 130:1873-1883. 10.1093/brain/awm109, 17584779.
109. Patterson ZR, Holahan MR. Understanding the neuroinflammatory response following concussion to develop treatment strategies. Front Cell Neurosci 2012, 6:58. 3520152, 23248582.
110. Willie JT, Lim MM, Bennett RE, Azarion AA, Schwetye KE, Brody DL. Controlled cortical impact traumatic brain injury acutely disrupts wakefulness and extracellular orexin dynamics as determined by intracerebral microdialysis in mice. J Neurotrauma 2012, 29:1908-1921. 10.1089/neu.2012.2404, 3390985, 22607167.
111. Chio CC, Chang CH, Wang CC, Cheong CU, Chao CM, Cheng BC, Yang CZ, Chang CP. Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-α. BMC Neurosci 2013, 14:33. 10.1186/1471-2202-14-33, 3636122, 23496862.
112. Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, DePuy V. Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept. CNS Drugs 2012, 26:1051-1070. 10.1007/s40263-012-0013-2, 23100196.
113. Deutschman CS, Raj NR, McGuire EO, Kelz MB. Orexinergic activity modulates altered vital signs and pituitary hormone secretion in experimental sepsis. Crit Care Med 2013, 41:e368-e375. 10.1097/CCM.0b013e31828e9843, 24105451.
114. Liu L, Mills PJ, Rissling M, Fiorentino L, Natarajan L, Dimsdale JE, Sadler GR, Parker BA, Ancoli-Israel S. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun 2012, 26:706-713. 10.1016/j.bbi.2012.02.001, 3372667, 22406004.
115. Kipnis J, Derecki NC, Yang C, Scrable H. Immunity and cognition: what do age-related dementia, HIV-dementia and 'chemo-brain' have in common?. Trends Immunol 2008, 29:455-463. 10.1016/j.it.2008.07.007, 18789764.
116. Weymann KB, Wood LJ, Zhu X, Marks DL. A role for orexin in cytotoxic chemotherapy-induced fatigue. Brain Behav Immun 2014, 37:84-94.
117. Jacob A, Brorson JR, Alexander JJ. Septic encephalopathy: inflammation in man and mouse. Neurochem Int 2011, 58:472-476. 10.1016/j.neuint.2011.01.004, 21219956.
118. Jurgens HA, Amancherla K, Johnson RW. Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice. J Neurosci 2012, 32:3958-3968. 10.1523/JNEUROSCI.6389-11.2012, 3353809, 22442063.
119. Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-α and IL-1β in HIV-associated dementia. Eur J Clin Invest 2006, 36:447-458. 10.1111/j.1365-2362.2006.01657.x, 16796601.
120. Sonneville R, Ferrand H, Tubach F, Roy C, Bouadma L, Klein IF, Foucrier A, Regnier B, Mourvillier B, Wolff M. Neurological complications of HIV infection in critically ill patients: clinical features and outcomes. J Infect 2011, 62:301-308. 10.1016/j.jinf.2011.02.003, 21329724.
121. Clark IA, Cowden WB. The pathophysiology of falciparum malaria. Pharmacol Ther 2003, 99:221-260. 10.1016/S0163-7258(03)00060-3, 12888113.
122. John CC, Panoskaltsis-Mortari A, Opoka RO, Park GS, Orchard PJ, Jurek AM, Idro R, Byarugaba J, Boivin MJ. Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. Am J Trop Med Hyg 2008, 78:198-205. 2254318, 18256412.
123. Dauvilliers Y, Bisser S, Chapotot F, Vatunga G, Cespuglio R, Josenando T, Buguet A. Hypocretin and human African trypanosomiasis. Sleep 2008, 31:348-354. 2276737, 18363311.
124. Clark IA. Does endotoxin cause both the disease and parasite death in acute malaria and babesiosis?. Lancet 1978, 2:75-77.
125. Clark IA, Awburn MM, Whitten RO, Harper CG, Liomba NG, Molyneux ME, Taylor TE. Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J 2003, 2:6. 10.1186/1475-2875-2-6, 154094, 12716455.
126. Clark IA, Awburn MM, Harper CG, Liomba NG, Molyneux ME. Induction of HO-1 in tissue macrophages and monocytes in fatal falciparum malaria and sepsis. Malar J 2003, 2:41. 10.1186/1475-2875-2-41, 317345, 14624702.
127. Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008, 13:1285-1295. 10.1634/theoncologist.2008-0130, 19019972.
128. Wilson CM, Gaber MW, Sabek OM, Zawaski JA, Merchant TE. Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys 2009, 74:934-941. 10.1016/j.ijrobp.2009.02.035, 19480972.
129. Parthsarathy V, Holscher C. The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain. Eur J Pharmacol 2012, 700:42-50.
130. Acuna-Goycolea C, van den Pol A. Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. J Neurosci 2004, 24:8141-8152. 10.1523/JNEUROSCI.1607-04.2004, 15371515.
131. Lowe XR, Bhattacharya S, Marchetti F, Wyrobek AJ. Early brain response to low-dose radiation exposure involves molecular networks and pathways associated with cognitive functions, advanced aging and Alzheimer's disease. Radiat Res 2009, 171:53-65. 10.1667/RR1389.1, 19138050.
132. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, Di Monte D, Dohi K, Melberg A, Lammers GJ, Nishida Y, Roelandse FW, Hungs M, Mignot E, Nishino S. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258. 10.1212/WNL.57.12.2253, 11756606.
133. Baumann CR, Hersberger M, Bassetti CL. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol 2006, 253:1232-1233. 10.1007/s00415-006-0146-7, 16598614.
134. Baumann CR, Scammell TE, Bassetti CL. Parkinson's disease, sleepiness and hypocretin/orexin. Brain 2008, 131:e91. 10.1093/brain/awm220, 17898005.
135. Compta Y, Santamaria J, Ratti L, Tolosa E, Iranzo A, Munoz E, Valldeoriola F, Casamitjana R, Rios J, Marti MJ. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009, 132:3308-3317. 10.1093/brain/awp263, 19858078.
136. Friedman LF, Zeitzer JM, Lin L, Hoff D, Mignot E, Peskind ER, Yesavage JA. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 2007, 68:793-794. 10.1212/01.wnl.0000256731.57544.f9, 17339595.
137. Fronczek R, van Geest S, Frolich M, Overeem S, Roelandse FW, Lammers GJ, Swaab DF. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging 2012, 33:1642-1650. 10.1016/j.neurobiolaging.2011.03.014, 21546124.
138. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 2007, 130:1586-1595. 10.1093/brain/awm097, 17491094.
139. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, Lammers GJ, Swaab DF. Hypocretin (orexin) loss and sleep disturbances in Parkinson's disease. Brain 2008, 131:e88.
140. Akbari E, Naghdi N, Motamedi F. The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 2007, 28:650-656. 10.1016/j.peptides.2006.11.002, 17161886.
141. Soya S, Shoji H, Hasegawa E, Hondo M, Miyakawa T, Yanagisawa M, Mieda M, Sakurai T. Orexin receptor-1 in the locus coeruleus plays an important role in cue-dependent fear memory consolidation. J Neurosci 2013, 33:14549-14557. 10.1523/JNEUROSCI.1130-13.2013, 24005305.
142. Wayner MJ, Armstrong DL, Phelix CF, Oomura Y. Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides 2004, 25:991-996. 10.1016/j.peptides.2004.03.018, 15203246.
143. Akbari E, Motamedi F, Davoodi FG, Noorbakhshnia M, Ghanbarian E. Orexin-1 receptor mediates long-term potentiation in the dentate gyrus area of freely moving rats. Behav Brain Res 2011, 216:375-380. 10.1016/j.bbr.2010.08.017, 20728473.
144. Yang L, Zou B, Xiong X, Pascual C, Xie J, Malik A, Sakurai T, Xie XS. Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice. J Neurosci 2013, 33:5275-5284. 10.1523/JNEUROSCI.3200-12.2013, 3640412, 23516292.
145. Jaeger LB, Farr SA, Banks WA, Morley JE. Effects of orexin-A on memory processing. Peptides 2002, 23:1683-1688. 10.1016/S0196-9781(02)00110-9, 12217429.
146. Ismail Z, Herrmann N, Rothenburg LS, Cotter A, Leibovitch FS, Rafi-Tari S, Black SE, Lanctot KL. A functional neuroimaging study of appetite loss in Alzheimer's disease. J Neurol Sci 2008, 271:97-103. 10.1016/j.jns.2008.03.023, 18495162.
147. Sheard JM, Ash S, Mellick GD, Silburn PA, Kerr GK. Malnutrition in a sample of community-dwelling people with Parkinson's disease. PLoS One 2013, 8:e53290. 10.1371/journal.pone.0053290, 3541272, 23326408.
148. Haynes AC, Jackson B, Chapman H, Tadayyon M, Johns A, Porter RA, Arch JR. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 2000, 96:45-51. 10.1016/S0167-0115(00)00199-3, 11102651.
149. Akiyama M, Yuasa T, Hayasaka N, Horikawa K, Sakurai T, Shibata S. Reduced food anticipatory activity in genetically orexin (hypocretin) neuron-ablated mice. Eur J Neurosci 2004, 20:3054-3062. 10.1111/j.1460-9568.2004.03749.x, 15579160.
150. Kunii K, Yamanaka A, Nambu T, Matsuzaki I, Goto K, Sakurai T. Orexins/hypocretins regulate drinking behaviour. Brain Res 1999, 842:256-261. 10.1016/S0006-8993(99)01884-3, 10526122.
151. Albert SG, Nakra BR, Grossberg GT, Caminal ER. Vasopressin response to dehydration in Alzheimer's disease. J Am Geriatr Soc 1989, 37:843-847.
152. Cutler DJ, Morris R, Sheridhar V, Wattam TA, Holmes S, Patel S, Arch JR, Wilson S, Buckingham RE, Evans ML, Leslie RA, Williams G. Differential distribution of orexin-A and orexin-B immunoreactivity in the rat brain and spinal cord. Peptides 1999, 20:1455-1470. 10.1016/S0196-9781(99)00157-6, 10698122.
153. Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, Scammell TE. Fos expression in orexin neurons varies with behavioral state. J Neurosci 2001, 21:1656-1662.
154. Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J, Peever J, Siegel JM. Release of hypocretin (orexin) during waking and sleep states. J Neurosci 2002, 22:5282-5286.
155. Takakusaki K, Takahashi K, Saitoh K, Harada H, Okumura T, Kayama Y, Koyama Y. Orexinergic projections to the cat midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy. J Physiol 2005, 568:1003-1020. 10.1113/jphysiol.2005.085829, 1464186, 16123113.
156. Zhang J, Li B, Yu L, He YC, Li HZ, Zhu JN, Wang JJ. A role for orexin in central vestibular motor control. Neuron 2011, 69:793-804. 10.1016/j.neuron.2011.01.026, 21338887.
157. Tsuneki H, Murata S, Anzawa Y, Soeda Y, Tokai E, Wada T, Kimura I, Yanagisawa M, Sakurai T, Sasaoka T. Age-related insulin resistance in hypothalamus and peripheral tissues of orexin knockout mice. Diabetologia 2008, 51:657-667. 10.1007/s00125-008-0929-8, 18256806.
158. Tsuneki H, Tokai E, Sugawara C, Wada T, Sakurai T, Sasaoka T. Hypothalamic orexin prevents hepatic insulin resistance induced by social defeat stress in mice. Neuropeptides 2013, 47:213-219. 10.1016/j.npep.2013.02.002, 23510906.
159. Vgontzas AN, Zoumakis E, Lin HM, Bixler EO, Trakada G, Chrousos GP. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-α antagonist. J Clin Endocrinol Metab 2004, 89:4409-4413. 10.1210/jc.2003-031929, 15356039.
160. Zamarron C, Maceiras F, Mera A, Gomez-Reino JJ. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. Ann Rheum Dis 2004, 63:88-90. 10.1136/ard.2003.007831, 1754718, 14672898.
161. Irwin MR, Olmstead R, Valladares EM, Breen EC, Ehlers CL. Tumor necrosis factor antagonism normalizes rapid eye movement sleep in alcohol dependence. Biol Psychiatry 2009, 66:191-195. 10.1016/j.biopsych.2008.12.004, 2761725, 19185287.
162. Thaci D, Galimberti R, Amaya-Guerra M, Rosenbach T, Robertson D, Pedersen R, Yang S, Kuligowski M, Boggs R. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. J Eur Acad Dermatol Venereol 2013, doi:10.1111/jdv.12207.
163. Takahashi S, Kapas L, Fang JD, Krueger JM. An anti-tumor necrosis factor antibody suppresses sleep in rats and rabbits. Brain Res 1995, 690:241-244. 10.1016/0006-8993(95)00609-T, 8535843.
164. Odessey R, Goldberg AL. Oxidation of leucine by rat skeletal muscle. Am J Physiol 1972, 223:1376-1383.
165. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005, 3:705-713. 10.1016/S1542-3565(05)00017-0, 16206505.
166. Mattick JS, Kamisoglu K, Ierapetritou MG, Androulakis IP, Berthiaume F. Branched-chain amino acid supplementation: impact on signaling and relevance to critical illness. Wiley Interdiscip Rev Syst Biol Med 2013, 5:449-460. 10.1002/wsbm.1219, 23554299.
167. Lim MM, Elkind J, Xiong G, Galante R, Zhu J, Zhang L, Lian J, Rodin J, Kuzma NN, Pack AI, Cohen AS. Dietary therapy mitigates persistent wake deficits caused by mild traumatic brain injury. Sci Transl Med 2013, 5:215ra173. 10.1126/scitranslmed.3007092, 3951738, 24337480.
168. Cole JT, Mitala CM, Kundu S, Verma A, Elkind JA, Nissim I, Cohen AS. Dietary branched chain amino acids ameliorate injury-induced cognitive impairment. Proc Natl Acad Sci USA 2010, 107:366-371. 10.1073/pnas.0910280107, 2806733, 19995960.
169. Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Gee CE, Jacobson LH, Laue G, Ofner S, Chaudhari V, Badiger S, Pandit C, Wagner J, Hoyer D. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. J Med Chem 2013, 56:7590-7607. 10.1021/jm4007627, 23964859.
170. Jia X, Yan J, Xia J, Xiong J, Wang T, Chen Y, Qi A, Yang N, Fan S, Ye J, Hu Z. Arousal effects of orexin A on acute alcohol intoxication-induced coma in rats. Neuropharmacology 2012, 62:775-783. 10.1016/j.neuropharm.2011.08.047, 21924278.
171. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007, 27:14239-14247. 10.1523/JNEUROSCI.3878-07.2007, 18160631.
172. Weinhold SL, Seeck-Hirschner M, Nowak A, Hallschmid M, Goder R, Baier PC. The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy. Behav Brain Res 2014, 262:8-13.
173. von der Goltz C, Koopmann A, Dinter C, Richter A, Grosshans M, Fink T, Wiedemann K, Kiefer F. Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence. Horm Behav 2011, 60:644-650. 10.1016/j.yhbeh.2011.08.017, 21945150.
174. Hasegawa E, Yanagisawa M, Sakurai T, Mieda M. Orexin neurons suppress narcolepsy via 2 distinct efferent pathways. J Clin Invest 2014, 124:604-616. 10.1172/JCI71017, 3904620, 24382351.